Spero Therapeutics (SPRO) Net Income towards Common Stockholders (2016 - 2026)

Spero Therapeutics has reported Net Income towards Common Stockholders for 11 years, with the latest figure at -$7.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 48.06% year-over-year to -$7.2 million; the trailing twelve-month figure through Mar 2026 stood at $15.2 million (up 120.72% YoY), and the FY2025 full-year result was $8.6 million, up 112.48% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$7.2 million, down from $31.5 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $55.1 million in Q4 2023, with the low at -$30.1 million in Q1 2022.
• Historically, Net Income towards Common Stockholders has averaged -$5.0 million across 5 years, with a median of -$11.9 million in 2023.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders tumbled 454.02% — and 2025, when it soared 230.92%.
• Spero Therapeutics' Net Income towards Common Stockholders stood at $27.5 million in 2022, then surged by 100.51% to $55.1 million in 2023, then plunged by 143.68% to -$24.1 million in 2024, then soared by 230.92% to $31.5 million in 2025, then tumbled by 122.85% to -$7.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$7.2 million (Q1 2026), $31.5 million (Q4 2025), and -$7.4 million (Q3 2025), per Business Quant data.